Last reviewed · How we verify

TEPEZZA — Competitive Intelligence Brief

TEPEZZA (TEPEZZA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IGF-1R inhibitor monoclonal antibody. Area: Immunology / Ophthalmology.

marketed IGF-1R inhibitor monoclonal antibody IGF-1R (Insulin-like Growth Factor-1 Receptor) Immunology / Ophthalmology Biologic Live · refreshed every 30 min

Target snapshot

TEPEZZA (TEPEZZA) — Amgen. TEPEZZA is a monoclonal antibody that blocks the insulin-like growth factor-1 receptor (IGF-1R) to reduce inflammation and tissue remodeling in thyroid eye disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TEPEZZA TARGET TEPEZZA Amgen marketed IGF-1R inhibitor monoclonal antibody IGF-1R (Insulin-like Growth Factor-1 Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IGF-1R inhibitor monoclonal antibody class)

  1. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TEPEZZA — Competitive Intelligence Brief. https://druglandscape.com/ci/tepezza. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: